US › Healthcare

Enlivex Therapeutics Ltd (ENLV)

US · Healthcare · Biotechnology

$2.11-2.76%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue
$0
Net profit
$1.24B
Profit YoY
+24115.7%
EPS
$-0.15
EPS estimate
$-0.02

EPS came in at -0.15 against a street estimate of -0.02 — a miss of 650.0%.

Key statistics

Market cap
$35.2M
P/E
0.0
Forward P/E
0.0
P/B
0.02
Book value
$122.27
EPS (TTM)
$382.20
52-week high
$31.50
52-week low
$1.80
50-day MA
$8.13
200-day MA
$13.01
Beta
1.52

Analyst view

Analysts rate Enlivex Therapeutics Ltd a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $300.00.

Shareholding

Insiders
81.40%
Institutions
1.44%

Largest institutional holders

FundStake
Diametric Capital, LP0.62%
ARK Investment Management LLC0.26%
Springbok Capital Management, LLC0.09%
Two Sigma Investments LLC0.06%
UBS Group AG0.06%
Bank of America Corp0.05%
Renaissance Technologies Corp0.05%
JPMorgan Chase & Co0.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Enlivex Therapeutics Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.